Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with significant therapeutic advances in managing type 2 diabetes and obesity.
- GLP-1RAs have expanded indications that now include cardiovascular and kidney disease management.
- Safety concerns regarding GLP-1RAs involve multiple organ systems.
- A review of adverse effects linked to GLP-1RAs is presented.
- The findings provide a basis for assessing the safe prescription of these medications.
Simplified